Sunshine Biopharma (SBFM) Leases (2019 - 2025)
Sunshine Biopharma (SBFM) has disclosed Leases for 5 consecutive years, with $820489.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases rose 51.53% year-over-year to $820489.0, compared with a TTM value of $820489.0 through Sep 2025, up 51.53%, and an annual FY2024 reading of $936037.0, up 44.72% over the prior year.
- Leases was $820489.0 for Q3 2025 at Sunshine Biopharma, down from $892817.0 in the prior quarter.
- Across five years, Leases topped out at $936037.0 in Q4 2024 and bottomed at $541468.0 in Q3 2024.
- Average Leases over 4 years is $730545.1, with a median of $719594.0 recorded in 2023.
- The sharpest move saw Leases decreased 20.69% in 2024, then soared 58.32% in 2025.
- Year by year, Leases stood at $760409.0 in 2022, then decreased by 14.94% to $646779.0 in 2023, then surged by 44.72% to $936037.0 in 2024, then fell by 12.34% to $820489.0 in 2025.
- Business Quant data shows Leases for SBFM at $820489.0 in Q3 2025, $892817.0 in Q2 2025, and $900890.0 in Q1 2025.